Dongsheng S. Xiong
State Key Laboratory Of Experimental Hematology, Tianjin Key Laboratory Of Cell Therapy For Blood Diseases, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020
Tianjin, 301600, China
Tianjin, 301600, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: July 04, 2024
Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma.
Journal: Oncoimmunology
Published: June 05, 2023
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity.
Journal: Cancer communications (London, England)
Published: January 27, 2023
Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.
Journal: Nature communications
Published: December 02, 2022
A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: July 07, 2021
A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer.
Journal: Frontiers in oncology
Published: October 16, 2020
Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: April 22, 2020
An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma.
Journal: Frontiers in oncology
Published: June 24, 2019
Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.
Journal: Journal of hematology & oncology
Published: January 02, 2019
Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1.
Journal: Cancer cell international
Published: November 14, 2018
Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells.
Journal: Human gene therapy
Published: November 02, 2018
SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Journal: Cancer chemotherapy and pharmacology
Published: July 30, 2018
Last Updated: 09/26/2026